BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25034106)

  • 1. Synthetic lethal genetic screens in Ras mutant cancers.
    Yu B; Luo J
    Enzymes; 2013; 34 Pt. B():201-19. PubMed ID: 25034106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of synthetic lethal interactions as cancer drug targets.
    Kuiken HJ; Beijersbergen RL
    Future Oncol; 2010 Nov; 6(11):1789-802. PubMed ID: 21142664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.
    Kacsinta AD; Dowdy SF
    Expert Opin Biol Ther; 2016; 16(2):161-72. PubMed ID: 26630128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
    Sacco E; Spinelli M; Vanoni M
    Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategies to target RAS-mutant cancers.
    Ryan MB; Corcoran RB
    Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Approaches to RAS Mutation.
    Scott AJ; Lieu CH; Messersmith WA
    Cancer J; 2016; 22(3):165-74. PubMed ID: 27341593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
    Scholl C; Fröhling S; Dunn IF; Schinzel AC; Barbie DA; Kim SY; Silver SJ; Tamayo P; Wadlow RC; Ramaswamy S; Döhner K; Bullinger L; Sandy P; Boehm JS; Root DE; Jacks T; Hahn WC; Gilliland DG
    Cell; 2009 May; 137(5):821-34. PubMed ID: 19490892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defeat mutant KRAS with synthetic lethality.
    Pang X; Liu M
    Small GTPases; 2017 Oct; 8(4):212-219. PubMed ID: 27463838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell.
    Paul JM; Templeton SD; Baharani A; Freywald A; Vizeacoumar FJ
    Trends Mol Med; 2014 Dec; 20(12):704-15. PubMed ID: 25446836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of K-Ras plasma membrane localization.
    Cho KJ; van der Hoeven D; Hancock JF
    Enzymes; 2013; 33 Pt A():249-65. PubMed ID: 25033808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
    Downward J
    Clin Cancer Res; 2015 Apr; 21(8):1802-9. PubMed ID: 25878361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the RAS oncogene.
    Takashima A; Faller DV
    Expert Opin Ther Targets; 2013 May; 17(5):507-31. PubMed ID: 23360111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugging RAS: Know the enemy.
    Papke B; Der CJ
    Science; 2017 Mar; 355(6330):1158-1163. PubMed ID: 28302824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying synthetic lethality for the selective targeting of cancer.
    McLornan DP; List A; Mufti GJ
    N Engl J Med; 2014 Oct; 371(18):1725-35. PubMed ID: 25354106
    [No Abstract]   [Full Text] [Related]  

  • 16. Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras.
    Wang T; Yu H; Hughes NW; Liu B; Kendirli A; Klein K; Chen WW; Lander ES; Sabatini DM
    Cell; 2017 Feb; 168(5):890-903.e15. PubMed ID: 28162770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using pooled miR30-shRNA library for cancer lethal and synthetic lethal screens.
    Lee LC; Gao S; Li Q; Luo J
    Methods Mol Biol; 2014; 1176():45-58. PubMed ID: 25030918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges.
    Shao YT; Ma L; Zhang TH; Xu TR; Ye YC; Liu Y
    Curr Top Med Chem; 2019; 19(23):2143-2157. PubMed ID: 31456522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNAi and HTS: exploring cancer by systematic loss-of-function.
    Willingham AT; Deveraux QL; Hampton GM; Aza-Blanc P
    Oncogene; 2004 Nov; 23(51):8392-400. PubMed ID: 15517021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS-targeted therapies: is the undruggable drugged?
    Moore AR; Rosenberg SC; McCormick F; Malek S
    Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.